GLP-1 agonists have known and unknown side effects and interactions, and you might play up the anxiety/fear card (ew)...
But diets have side-effects, too. Hunger. Disordered eating. Social anxiety. Are you honest with clients about those possibilities? /2
Maybe longevity?
You don't ever come off GLP-1 agonists. Users are locked in if they want to keep the weight off...
Do you coach people to achieve their goals without you? Can your business model handle frequently losing clients?
Do you follow up to know if it sticks? /3
Maybe thoroughness?
Many people have goals beyond weight loss, and offering many benefits besides scale-weight is appealing...
But how consistently effective are your methods at accomplishing deep change? You may include it in the package, but how many see them? /4
Maybe collaboration?
Maybe you'll work with a clinic to help clients build fitness, learn new skills, and preserve as much lean muscle mass as possible while they lose weight through the help of these drugs.
Costs, credentialing, and insurance become factors... /5
Maybe values?
This is a gross angle to take, but are you going to niche down and appeal to the hyper-individualistic, righteous, often right-leaning audience that rejects medications on purity grounds?
Is there another protected niche you can secure?
/6
From an industry perspective, these trials have quantified the results that coaches and organizations have often failed (or refused) to quantify for years
They've set the bar, and our clients are better able to track results now than ever before
It's put up or shut up. /x
• • •
Missing some Tweet in this thread? You can try to
force a refresh
There were 234,000,000 American adults 18 and over in 2020. Let's use that as our number for who needs to be served (leaving kids out of the equation) /1
Let's assume that health insurance covers $30 of a monthly gym membership and $100 of a month's PT costs. Ignoring how it would affect health insurance premiums and distort the market (gyms would, of course, charge more) that comes with a price tag of 365 billion/year /2